Differential exoprotease activities confer tumor-specific serum peptidome patterns

Journal of Clinical Investigation

Volumn 116, Issue 1, 2006, Pages 271-284

  Villanueva, Josep ^a   Shaffer, David R ^a   Philip, John ^a   Chaparro, Carlos A ^a   Erdjument Bromage, Hediye ^a   Olshen, Adam B ^a   Fleisher, Martin ^a   Lilja, Hans ^a   Brogi, Edi ^a   Boyd, Jeff ^a   Sanchez Carbayo, Marta ^a   Holland, Eric C ^a   Cordon Cardo, Carlos ^a   Scher, Howard I ^a   Tempst, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT; EXOPEPTIDASE; PEPTIDE; TUMOR MARKER;

ACCURACY; ARTICLE; BLOOD CLOTTING; CANCER PATIENT; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO STUDY; EXTRACTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DEGRADATION; SAMPLE; SEQUENCE ANALYSIS; SERUM; SOLID TUMOR; VALIDATION PROCESS;

AMINO ACID SEQUENCE; EXOPEPTIDASES; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEOME; REFERENCE VALUES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 31044436630     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI26022     Document Type: Article

References (79)

1. Lander, E.S., et al. 2001. Initial sequencing and analysis of the human genome. Nature. 409:860-921.
2. Hood, L. 2003. Leroy Hood expounds the principles, practice and future of systems biology. Drug Discov. Today. 8:436-438.
3. Etzioni, R., et al. 2003. The case for early detection. Nat. Rev. Cancer. 3:243-252.
4. Chung, C.H., Bernard, P.S., and Perou, C.M. 2002. Molecular portraits and the family tree of cancer. Nat. Genet. 32(Suppl.):533-540.
5. Staudt, L.M. 2002. Gene expression profiling of lymphoid malignancies. Annu. Rev. Med. 53:303-318.
6. Anderson, N.L., and Anderson, N.G. 2002. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics. 1:845-867.
7. Adkins, J.N., et al. 2002. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol. Cell. Proteomics. 1:947-955.
8. Sidransky, D. 2002. Emerging molecular markers of cancer. Nat. Rev. Cancer. 2:210-219.
9. Bidart, J.M., et al. 1999. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin. Chem. 45:1695-1707.
10. Jortani, S.A., Prabhu, S.D., and Valdes, R., Jr. 2004. Strategies for developing biomarkers of heart failure. Clin. Chem. 50:265-278.
11. Watts, N.B. 1999. Clinical utility of biochemical markers of bone remodeling. Clin. Chem. 45:1359-1368.
12. Gillette, M.A., Mani, D.R., and Carr, S.A. 2005. Place of pattern in proteomic biomarker discovery. J. Proteome Res. 4:1143-1154.
13. Hugosson, J., et al. 2003. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J. Urol. 169:1720-1723.
14. Ghosh, A., Wang, X., Klein, E., and Heston, W.D. 2005. Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res. 65:727-731.
15. Richter, R., et al. 1999. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J. Chromatogr. B Biomed. Sci. Appl. 726:25-35.
16. Tirumalai, R.S., et al. 2003. Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomics. 1:1096-1103.
17. Koomen, J.M., et al. 2005. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res. 4:972-981.
18. Villanueva, J., et al. 2004. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 76:1560-1570.
19. Petricoin, E.F., et al. 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:572-577.
20. Adam, B.L., et al. 2002. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62:3609-3614.
21. Li, J., Zhang, Z., Rosenzweig, J., Wang, Y.Y., and Chan, D.W. 2002. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48:1296-1304.
22. Ebert, M.P., et al. 2004. Identification of gastric cancer patients by serum protein profiling. J. Proteome Res. 3:1261-1266.
23. Ornstein, D.K., et al. 2004. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J. Urol. 172:1302-1305.
24. Conrads, T.P., et al. 2004. High-resolution serum proteomic features for ovarian cancer detection. Endocr. Relat. Cancer. 11:163-178.
25. Coombes, K.R., Morris, J.S., Hu, J., Edmonson, S.R., and Baggerly, K.A. 2005. Serum proteomics profiling-a young technology begins to mature. Nat. Biotechnol. 23:291-292.
26. Diamandis, E.P. 2004. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics. 3:367-378.
27. Check, E. 2004. Proteomics and cancer: running before we can walk? Nature. 429:496-497.
28. Ransohoff, D.F. 2005. Opinion: bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer. 5:142-149.
29. Villanueva, J., et al. 2005. Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 4:1060-1072.
30. Marshall, J., et al. 2003. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J. Proteome Res. 2:361-372.
31. Bergen, H.R., 3rd, et al. 2003. Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry. Dis. Markers. 19:239-249.
32. Zhang, Z., et al. 2004. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64:5882-5890.
33. Weinberger, S.R., Dalmasso, E.A., and Fung, E.T. 2002. Current achievements using ProteinChip Array technology. Curr. Opin. Chem. Biol. 6:86-91.
34. Kapp, E.A., et al. 2003. Mining a tandem mass spectrometry database to determine the trends and global factors influencing peptide fragmentation. Anal. Chem. 75:6251-6264.
35. Gao, J., Opiteck, G.J., Friedrichs, M.S., Dongre, A.R., and Hefta, S.A. 2003. Changes in the protein expression of yeast as a function of carbon source. J. Proteome Res. 2:643-649.
36. Fach, E.M., et al. 2004. In vitro biomarker discovery for atherosclerosis by proteomics. Mol. Cell. Proteomics. 3:1200-1210.
37. Jandl, J.H. 1996. Blood: textbook of hematology. Little, Brown and Co. New York, New York, USA. 1510 pp.
38. Sahu, A., and Lambris, J.D. 2001. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol. Rev. 180:35-48.
39. Abbasciano, V., Levato, F., and Zavagli, G. 1987. Specificity of fibrinopeptide A (FpA) as a marker for gastrointestinal cancers before and after surgery. Med. Oncol. Tumor Pharmacother. 4:75-79.
40. Auger, M.J., Galloway, M.J., Leinster, S.J., McVerry, B.A., and Mackie, M.J. 1987. Elevated fibrinopeptide A levels in patients with clinically localised breast carcinoma. Haemostasis. 17:336-339.
41. Stewart, J.M. 2003. Bradykinin antagonists as anticancer agents. Curr. Pharm. Des. 9:2036-2042.
42. Kato, H., Matsumura, Y., and Maeda, H. 1988. Isolation and identification of hydroxyproline analogues of bradykinin in human urine. FEBS Lett. 232:252-254.
43. Salier, J.P., Rouet, P., Raguenez, G., and Daveau, M. 1996. The inter-alpha-inhibitor family: from structure to regulation. Biochem. J. 315:1-9.
44. Nishimura, H., et al. 1995. cDNA and deduced amino acid sequence of human PK-120, a plasma kallikrein-sensitive glycoprotein. FEBS Lett. 357:207-211.
45. Belt, K.T., Carroll, M.C., and Porter, R.R. 1984. The structural basis of the multiple forms of human complement component C4. Cell. 36:907-914.
46. July, L.V., et al. 2002. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 50:179-188.
47. Scaltriti, M., et al. 2004. Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int. J. Cancer. 108:23-30.
48. Miyake, H., Gleave, M., Kamidono, S., and Hara, I. 2002. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology. 59:150-154.
49. Jiang, W.G., Ablin, R., Douglas-Jones, A., and Mansel, R.E. 2003. Expression of transglutaminases in human breast cancer and their possible clinical significance. Oncol. Rep. 10:2039-2044.
50. Tietz, N.W. 1995. Clinical guide to laboratory tests. Philadelphia, Pennsylvania, USA. W.B. Saunders Co. 1096 pp.
51. Sanderink, G.J., Artur, Y., and Siest, G. 1988. Human aminopeptidases: a review of the literature. J. Clin. Chem. Clin. Biochem. 26:795-807.
52. Silveira, P.F., Gil, J., Casis, L., and Irazusta, J. 2004. Peptide metabolism and the control of body fluid homeostasis. Curr. Med. Chem. Cardiovasc. Hematol. Agents. 2:219-238.
53. Mitsui, T., Nomura, S., Itakura, A., and Mizutani, S. 2004. Role of aminopeptidases in the blood pressure regulation. Biol. Pharm. Bull. 27:768-771.
54. Nesheim, M., et al. 1997. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb. Haemost. 78:386-391.
55. Ito, N., et al. 2004. ADAMs, a disintegrin and metalloproteinases, mediate shedding of oxytocinase. Biochem. Biophys. Res. Commun. 314:1008-1013.
56. van Hensbergen, Y., et al. 2002. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin. Cancer Res. 8:3747-3754.
57. Martinez, J.M., et al. 1999. Aminopeptidase activities in breast cancer tissue. Clin. Chem. 45:1797-1802.
58. Matrisian, L.M., Sledge, G.W., Jr., and Mohla, S. 2003. Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res. 63:6105-6109.
59. Egeblad, M., and Werb, Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer. 2:161-174.
60. Rao, J.S. 2003. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer. 3:489-501.
61. Moffatt, S., Wiehle, S., and Cristiano, R.J. 2005. Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13. Hum. Gene Ther. 16:57-67.
62. Kehlen, A., Lendeckel, U., Dralle, H., Langner, J., and Hoang-Vu, C. 2003. Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res. 63:8500-8506.
63. Rocken, C., et al. 2004. Ectopeptidases are differentially expressed in hepatocellular carcinomas. Int. J. Oncol. 24:487-495.
64. Carl-McGrath, S., et al. 2004. The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer. Int. J. Oncol. 25:1223-1232.
65. Kojima, K., et al. 1987. Serum activities of dipeptidyl-aminopeptidase II and dipeptidyl-aminopeptidase IV in tumor-bearing animals and in cancer patients. Biochem. Med. Metab. Biol. 37:35-41.
66. Essler, M., and Ruoslahti, E. 2002. Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc. Natl. Acad. Sci. U. S. A. 99:2252-2257.
67. Carrera, M.P., et al. 2005. Serum enkephalin-degrading aminopeptidase activity in N-methyl nitrosourea-induced rat breast cancer. Anticancer Res. 25:193-196.
68. Pulido-Cejudo, G., et al. 2004. A monoclonal antibody driven biodiagnostic system for the quantitative screening of breast cancer. Biotechnol. Lett. 26:1335-1339.
69. Suganuma, T., et al. 2004. Regulation of aminopeptidase A expression in cervical carcinoma: role of tumor-stromal interaction and vascular endothelial growth factor. Lab. Invest. 84:639-648.
70. Selvakumar, P., et al. 2004. High expression of methionine aminopeptidase 2 in human colorectal adenocarcinomas. Clin. Cancer Res. 10:2771-2775.
71. Ni, R.Z., Huang, J.F., Xiao, M.B., Li, M., and Meng, X.Y. 2003. Glycylproline dipeptidyl aminopeptidase isoenzyme in diagnosis of primary hepatocellular carcinoma. World J. Gastroenterol. 9:710-713.
72. Sheppard, G.S., et al. 2004. 3-Amino-2-hydroxyamides and related compounds as inhibitors of methionine aminopeptidase-2. Bioorg. Med. Chem. Lett. 14:865-868.
73. Griffith, E.C., et al. 1998. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc. Natl. Acad. Sci. U. S. A. 95:15183-15188.
74. Pasqualini, R., et al. 2000. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60:722-727.
75. Petrovic, N., Bhagwat, S.V., Ratzan, W.J., Ostrowski, M.C., and Shapiro, L.H. 2003. CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells. J. Biol. Chem. 278:49358-49368.
76. O'Malley, P.G., Sangster, S.M., Abdelmagid, S.A., Bearne, S.L., and Too, C.K. 2005. Characterization of a novel, cytokine-inducible carboxypeptidase-D isoform in hematopoietic tumor cells. Biochem. J. 390:665-673.
77. Fair, W.R., Israeli, R.S., and Heston, W.D. 1997. Prostate-specific membrane antigen. Prostate. 32:140-148.
78. Marker, P.C., Donjacour, A.A., Dahiya, R., and Cunha, G.R. 2003. Hormonal, cellular, and molecular control of prostatic development. Dev. Biol. 253:165-174.
79. Benjamini, Y., and Hochberg, Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. (Ser. B.) 57:289-300.